Previous page Next page Bottom Top One level up Home

Cancer

Webpages concerning "Cancer"

Karyon is a research intensive molecular biology company. It focuses on development, patenting and commercialization of tissue specific targeting compounds for use in early diagnosis and therapy.
http://www.karyon.fi/
Keywords:
Karyon, company, research, intensive, drug carrier information, biology, cancer, target, cell, tissue, specific, targeting, compound, diagnosis, therapy, innovative

http://www.karyon.fi/

Maxim is a global biopharmaceutical company with a diverse pipeline targeting life-threatening cancers, hepatitis C, and liver diseases
http://www.maxim.com/
Keywords:
Maxim Pharmaceuticals, histamine, Ceplene, cancer, hepatitis C, liver, Maxim Pharmaceuticals, melanoma, HCV, hep C, melanoma, hepatitis C, Phase 3, Phase III, apoptosis, oncology, acute myelogenous leukemia, AML, renal cell carcinoma, kidney cancer, leukemia, malignant melanoma, radiation dermatitis, oral mucositis, apoptosis, immunotherapy, histamine, cytokine, interleukin-2, IL-2, interferon, ...

http://www.maxim.com/

PNP Therapeutics, Inc. - Biotechnology for the treatment of cancer - Birmingham, Alabama USA
http://www.pnptherapeutics.com/
Keywords:
pnp, therapeutics, biotechnology, escherichia coli, purine, nucleoside, phosphorylase, prodrugs, connexins, MeP-dR, vulcan, medical, ventures, cancer, drug

http://www.pnptherapeutics.com/

AC Immune SA is a product company with a focus on the area of CNS (conformational) diseases and cancer. Its approach consists of the combination of an immunology and a chemistry platform technology.
http://www.acimmune.com/
Keywords:
ac immune, acimmune, company, product company, CNS, conformational, diseases, cancer, immunology, chemistry platform technology, chemistry technology, lausanne, switzerland

http://www.acimmune.com/

Acrongenomics Inc., ( OTCBB : AGNM ) nanotechnology company. Acrongenomics reshaped key IVD applications such as PCR, ELISA, Real-Time PCR via its unique Nano-JETA technology by integrating nanotechnology into molecular biology. Unique nanomolecular diagnostics for cancer detection
http://www.acrongen.com/
Keywords:
molecular diagnostics, nanotechnology, nanobiotechnology, real time pcr, cancer detection kit, cancer, Nano-JETA, neo-epcam, ep-cam, pcr, elisa, ivd, in vitro diagnostics, her, epithelials, expression

http://www.acrongen.com/

Biomira is a biotechnology company applying its leading technology in immunotherapy and organic chemistry for the development of cancer therapeutics. The Company's commitment to the development of products for the treatment of cancer is currently focused on synthetic therapeutic vaccines and innovative strategies for immunotherapy of cancer. We are the Can...
http://www.biomira.com/
Keywords:
cancer vaccines, cancer vaccine, breast cancer, lung cancer, cancer, Biomira, lymphoma, idiotypic vaccines, oncology trials, breast, cancer , trials, clinical trials, THERATOPE, BLP 25, biotechnology, vaccines, Biomira USA

http://www.biomira.com/

Biotica is a pharmaceutical company focused on the discovery and development of novel anti-cancer drugs through synthetic biology of natural products known as polyketides, such as rapamycin analogues
http://www.biotica.co.uk/
Keywords:
Biotica technology Ltd, polyketides, microbiology, chemistry, Biotica, Technology, Limited Drug, discovery'Biosynthesis, Polyketides, Cancer, Proliferative diseases, Streptomyces, Polyketide synthase, Natural product, Erythromycin, Monensin, Rapamycins, Combinatorial biosynthesis, FK506, Epothilone, Amphotericin, Spinosyn, Avermectin, Saccharopolyspora erythraea, Streptomyces hygroscopicus, ...

http://www.biotica.co.uk/

ex vivo drug sensitivity studies using the Differential Staining Cytotoxicity assay, assessing cytotoxic drug sensitivity for chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML or ANLL) and non-Hodgkin's lymphoma. Also international service for consultant haematologists/ oncologists, testing cells from their patients for ex vivo drug response to a panel of cytotoxic drugs. Also new...
http://www.caltri.org/
Keywords:
Bath, cancer, research, Cancer, research, Medical, research, Drug, research, New, Drug, screening, Differential, Staining, Cytotoxicity, leukaemia, lymphoma, cancer, chronic, lymphocytic, leukaemia, acute, myeloid, leukaemia, non-Hodgkin's, lymphoma, consultant, haematologists, oncologists, cytotoxic, drugs, Dr, Andrew, Bosanquet, cancer, treatment, disc, trac, tumour, response, to, ...

http://www.caltri.org/

At Genentech BioOncology, we're fundamentally transforming the way cancer is treated, with the goal of moving cancer towards a more chronic and manageable disease. BioOncology.com, dedicated to sharing information and ideas about a new approach to cancer therapy.
http://www.biooncology.com/
Keywords:
cancer treatment therapy

http://www.biooncology.com/

Cancer Vaccine, Cancer Vaccine Research, Immunotherapy, Immune System, Immunotherapy in Oncology, Cancer Clinical Trial, Stage III Colorectal Cancer, Stage 3 Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer Treatment, Colorectal Cancer Therapy, Colorectal Cancer Clinical Trial, Colon Cancer Treatment, Vaccine Colon Cancer, Stage III Colon Cancer, Stage 3 Colon Cancer, Colon Cance...
http://www.cancervaccines.com/
Keywords:
Ongoing, clinical, trials, for, a, new, treatment, approach, for, cancer, will, examine, another, way, of, treating, colorectal, melanoma, and, breast, cancer:, using, a, vaccine.

http://www.cancervaccines.com/

The Cancer Survival Toolbox is a free, self-learning audio program that has been developed by leading cancer organizations.
http://www.gene.com/gene/products/education/oncology/cst/
Keywords:
cancer survival, breast cancer survival, cancer survival toolbox, breast cancer

http://www.gene.com/gene/products/education/oncology/cst/

Hannah Cell Science provides analytical services and research partnerships in cell biology. We specialise in the biology of the definitive mammalian tissue - the mammary gland, and offer leading edge research and analysis relevant to breast cancer, lactation and milk. Hannah Cell Science is a division of Hannah InterActions Ltd, a partner company of the Hannah Research Institute. Through this link...
http://www.hannahcellscience.com/
Keywords:
hannah, interactions, cell biology, biotechnology, biomedicine, analytical services, research partnership, products, cell culture, quantitative histology, breast cancer, mammary, apoptosis, lactation, regenerative medicine, milk, CellAudit Analytical Services, CellAudit, histology, Quantitative histology, cell proliferation, cell death, cell typing, caspase, BioInterActions, Biosensor, ...

http://www.hannahcellscience.com/

Cancer research by HEAL corporation examines natural products and body metabolism that prevents and reverses oncogenesis.
http://www.healcorp.net/
Keywords:
tocopherol, tocopheryl-succinate, vitamin E succinate, Vitamin E acetate, Vitamin A, Retinol, Retinoic acid, cancer, trout hepatoma, cellular carcinoma, liver cirhosis, Polyunsaturated fatty acids, detoxifying enzyme, Catalase, PUFA dependant catalase, Cancer prevention, apoptosis

http://www.healcorp.net/

HEXAL Gentech is an innovative company dedicated to develop and to market novel molecular therapeutics and diagnostics for cancer and infectious diseases.
http://www.hexal-gentech.de/
Keywords:
Tumor, Tumour, Krebs, Cancer, minimal, residual, disease, MRD, blood, early, detection, circulating, disseminated, bones, marrow, peripheral, PCR, RT-PCR, immunocytochemistry, ICC, FISH, flow, cytometer, validations, stainings, specific, micrometastasis, metastasis, breasts, colons, lungs, prostates, patients, analysis, new, methods, carcinomas, cells, immunomagnetic, dynal, miltenyi, becton, ...

http://www.hexal-gentech.de/

The first products to be developed will be used for early diagnosis of cancer, followed by products that will aid in the imaging and treatment of cancer.
http://www.biomoda.com/
Keywords:
biotechnology, cancer, cancer treatment, cancer detection, porphyrin, TCPP, cancer cells, research, technology, new mexico, biomoda, bio moda, adot

http://www.biomoda.com/

CancerVax is a biotechnology company focused on research, development, and commercialization of novel products for treatment and control of cancer.
http://www.cancervax.com/
Keywords:
Angiogenesis, angiogenesis inhibitor, cancer, cancer treatment, cancer vaccine, CancerVax, CancerVax vaccine, Canvaxin, Cell Matrix, melanoma clinical trial, colon cancer, David Hale, immunotherapy, melanoma, melanoma vaccine, monoclonal antibody, vaccine

http://www.cancervax.com/

Onyvax is an early-stage biotechnology company focussed on the development of cancer therapies that employ the selectivity and power of the immune system to seek and destroy tumour cells.
http://www.onyvax.com/
Keywords:
trial, research, cancer, biotechnology, UK, immune, immunotherapy, antibody, oncology, colorectal, vaccine, St George's, prostate vaccine, prostate treatment, prostate therapy, prostate cancer, prostate clinical trial

http://www.onyvax.com/

a biotherapy company that is rapidly emerging as a leader in activated cell technology for cancer therapy.
http://www.cancer-therapeutics.com/
Keywords:
cancer, biotherapy, tumor, il-2, kidney, renal, melanoma, cryo, freezing, vaccine, t-cells, lymphocytes, autologous

http://www.cancer-therapeutics.com/

liver cancer and adult stem cell research and development of liver cancer therapy in Thailand
http://www.siam-lifescience.com/
Keywords:
liver cancer research, Thailand, adult stem cells, hepatology, S9, and, primary, human, hepatocytes

http://www.siam-lifescience.com/

http://www.allos.com/

http://www.allos.com/

http://www.amynon.com/

http://www.amynon.com/

http://www.austcancer.com.au/

http://www.austcancer.com.au/

http://www.ilexonc.com/

http://www.ilexonc.com/

http://www.neorx.com/

http://www.neorx.com/

http://www.oncogene.com/

http://www.oncogene.com/

Pivotal BioSciences is an early-stage company dedicated to the development and commercialization of innovative cancer therapies.
http://www.pivotalbiosciences.com/
Keywords:
Biotechnology, cancer immunotherapy, novel cancer therapy

http://www.pivotalbiosciences.com/

http://www.tapestrypharma.com/

http://www.tapestrypharma.com/

TopoTarget's mission is to deliver improved cancer treatments to patients
http://www.topotarget.com/

http://www.topotarget.com/

http://www.intergenetics.com/index1.html

http://www.intergenetics.com/index1.html

http://www.genesegues.com/

http://www.genesegues.com/

http://www.predictivediagnostics.com/

http://www.predictivediagnostics.com/

http://www.bostonlifesciences.com/

http://www.bostonlifesciences.com/

http://www.celticbio.com/

http://www.celticbio.com/

http://www.crusadelabs.co.uk/

http://www.crusadelabs.co.uk/

Help building the largest human-edited directory of the web
Suggest URL - Open Directory Project - Become an editor
directopedia.org uses links and structure from dmoz Open Directory Project.
The contents has been generating using technology developed by scientec.

Wikipedia-Article "Cancer"

For other uses, see Cancer (disambiguation).
When normal cells are damaged beyond repair, they are eliminated by apoptosis.  Cancer cells avoid apoptosis and continue to multiply in an unregulated manner.
Enlarge
When normal cells are damaged beyond repair, they are eliminated by apoptosis. Cancer cells avoid apoptosis and continue to multiply in an unregulated manner.

Cancer is a class of diseases characterized by uncontrolled division of cells and the ability of these cells to invade other tissues, either by direct growth into adjacent tissue (invasion) or by implantation into distant sites (metastasis). This unregulated growth is caused by damage to DNA, resulting in mutations to genes that control cell division. Several mutations are required to transform a normal cell into a malignant cell. These mutations are often caused by chemicals or physical agents called carcinogens, the best known being tobacco smoke. Some mutations can be inherited.

The word cancer is not used in medicine as it lacks precision, but remains the common name for this group of diseases in most languages. Instead, scientists and physicians use the word neoplasm (Latin neoplasia, new form). Tumor ("swelling" in Latin) is a more general term that describes an abnormal mass. In medicine, tumor is not synonymous with neoplasm; most tumors are not neoplasm, but rather inflammation surrounding an infection. Furthermore, many neoplasms do not cause a tumor, e.g. leukemia and myeloma. In the common language, however, tumor is synonymous with neoplasm. Tumors (and therefore neoplasms) can be malignant or benign. Therefore, cancer is synonymous with malignant tumor or, in medical language, malignant neoplasm.

Cancer can cause many different symptoms, depending on the site and character of the malignancy and whether there is metastasis. Usually, cancer is painless at an early stage. A definitive diagnosis usually requires the histologic examination of tissue by a specialized physician called a pathologist. This tissue is obtained by biopsy or surgery. Once diagnosed, cancer is usually treated with surgery, chemotherapy and/or radiation.

If untreated, most cancers eventually cause death; cancer is one of the leading causes of death in developed countries. Most cancers can be treated and many cured, especially if treatment begins early. Many forms of cancer are associated with environmental factors, which may be avoidable. Cigarette smoking leads to more cancers than any other environmental factor.

Contents

History

Hippocrates described several kinds of cancers. He called benign tumours oncos, Greek for swelling, and malignant tumours carcinos, Greek for crab or crayfish. This strange choice of name probably comes from the appearance of the cut surface of a solid malignant tumour, with a roundish hard center surrounded by pointy projections, vaguely resembling the silhouette of a crab. He later added the suffix -oma, Greek for swelling, giving the name carcinoma. Today, carcinoma is the medical term for a malignant tumour derived from epithelial cells. It is Celsus who translated carcinos into the latin cancer, also meaning crab. Galen used "oncos" to describe all tumours, the root for the modern word oncology.[Citation needed]

Classification and nomenclature

Cancers are classified by the type of cell that resembles the tumor and, therefore, the tissue presumed to be the origin of the tumor. The following general categories are usually accepted:

Malignant tumors are usually named using the Latin or Greek root of the organ as a prefix and the above category name as the suffix. For instance, a malignant tumor of liver cells is called hepatocarcinoma; a malignant tumor of the fat cells is called liposarcoma. For common cancers, the English organ name is used. For instance, the most common type of breast cancer is called ductal carcinoma of the breast or mammary ductal carcinoma. Here, the adjective ductal refers to the appearance of the cancer under the microscope, resembling normal breast ducts.

Benign tumors are named using -oma as a suffix. For instance, a benign tumor of the smooth muscle of the uterus is called leiomyoma (the common name of this frequent tumor is fibroid)

Adult cancers

In the USA and other developed countries, cancer is presently responsible for about 25% of all deaths[1]. On a yearly basis, 0.5% of the population is diagnosed with cancer.

For adult males in the United States, the most common cancers are prostate cancer (33% of all cancer cases), lung cancer (13%), colorectal cancer (10%), bladder cancer (7%) and cutaneous melanoma (5%). As a cause of death lung cancer is the most common (31%) cause, followed by prostate cancer (10%), colorectal cancer (10%), pancreatic cancer (5%) and leukemia (4%)[1].

For adult females in the United States, breast cancer is the most common cancer (32% of all cancer cases) followed by lung cancer (12%), colorectal cancer (11%), endometrial cancer (6%, uterus) and non-Hodgkin's lymphoma (4%). By cause of death, lung cancer is again the most common (27% of all cancer deaths), followed by breast cancer (15%), colorectal cancer (10%), ovarian cancer (6%) and pancreatic cancer (6%)[1].

These statistics vary substantially in other countries.

Childhood cancers

Cancer can also occur in young children and adolescents. Here, the aberrant genetic processes that fail to safeguard against the clonal proliferation of cells with unregulated growth potential occur early in life and can progress quickly.

The age of peak incidence of cancer in children occurs during the first year of life. Leukemia (usually ALL) is the most common infant malignancy (30%), followed by the central nervous system cancers and neuroblastoma. The remainder consists of Wilms' tumor, lymphomas, rhabdomyosarcoma (arising from muscle), retinoblastoma, osteosarcoma and Ewing's sarcoma[1].

Female infants and male infants have essentially the same overall cancer incidence rates, but white infants have substantially higher cancer rates than black infants for most cancer types. Relative survival for infants is very good for neuroblastoma, Wilms' tumor and retinoblastoma, and fairly good (80%) for leukemia, but not for most other types of cancer.

Causes and pathophysiology

Main article: Carcinogenesis

Origins of cancer

Cell division (proliferation) is a physiological process that occurs in almost all tissues and under many circumstances. Normally the balance between proliferation and cell death is tightly regulated to ensure the integrity of organs and tissues. Mutations in DNA that lead to cancer disrupt these orderly processes.

The uncontrolled and often rapid proliferation of cells can lead to either a benign tumor or a malignant tumor (cancer). Benign tumors do not spread to other parts of the body or invade other tissues, and they are rarely a threat to life unless they extrinsically compress vital structures. Malignant tumors can invade other organs, spread to distant locations (metastasize) and become life-threatening.

Molecular biology

Cancers are caused by a series of mutations.  Each mutation alters the behavior of the cell somewhat.
Enlarge
Cancers are caused by a series of mutations. Each mutation alters the behavior of the cell somewhat.

Carcinogenesis (meaning literally, the creation of cancer) is the process of derangement of the rate of cell division due to damage to DNA. Cancer is, ultimately, a disease of genes. In order for cells to start dividing uncontrollably, genes which regulate cell growth must be damaged. Proto-oncogenes are genes which promote cell growth and mitosis, a process of cell division, and tumor suppressor genes discourage cell growth, or temporarily halts cell division from occurring in order to carry out DNA repair. Typically, a series of several mutations to these genes are required before a normal cell transforms into a cancer cell.

Proto-oncogenes, promote cell growth through a variety of ways. Many can produce hormones, a "chemical messenger" between cells which encourage mitosis, the effect of which depends on the signal transduction of the receiving tissue or cells. Some are responsible for the signal transduction system and signal receptors in cells and tissues themselves, thus controlling the sensitivity to such hormones. They often produce mitogens, or are involved in transcription of DNA in protein synthesis, which create the proteins and enzymes is responsible for producing the products and biochemicals cells use and interact with.

Mutations in proto-oncogenes will modify their function. If their function is modified so that they become overexpressed and thus produce more proteins of which they are coded for, thus becoming overactive. When this happens, they become oncogenes, and thus cells have a higher chance to divide excessively and uncontrollably. Frustratingly, the chance of cancer cannot be reduced by removing proto-oncogenes from the genome as they are critical for growth, repair and homeostasis of the body. It is only when they become mutated, that the signals for growth become excessive.

Tumor suppressor genes code for anti-proliferation signals and proteins that suppress mitosis and cell growth. Generally tumor suppressors are transcription factors that are activated by cellular stress or DNA damage. Often DNA damage will cause the presence of free-floating genetic material as well as other signs, and will trigger enzymes and pathways which lead to the activation fo tumor suppressor geenes. The functions of such genes is to arrest the progression of cell cycle in order to carry out DNA repair, preventing mutations from passed on to daughter cells. Canonical tumor suppressors include the p53 gene, which is a transcription factor activated by many cellular stress including hypoxia and ultraviolet radiation damage.

However, a mutation can damage the tumor suppressor gene itself, or the signal pathway which activates it, "switching it off". The invariable consequence of this is that DNA repair is hindered or inhibited: DNA damage accumulates without repair, inevitably leading to cancer.

In general, mutations in both types of genes are required for cancer to occur. For example, a mutation limited to one oncogene would be suppressed by normal mitosis control and tumor suppressor genes, which was first hypothesised by the Knudson hypothesis. A mutation to only one tumor suppressor gene would not cause cancer either, due to the presence of many "backup" genes that duplicate its functions. It is only when enough proto-oncogenes have mutated into oncogenes, and enough tumor suppressor genes deactivated or damaged, that the signals for cell growth overwhelm the signals to regulate it, that cell growth quickly spirals out of control. Often, because these genes regulate the processes that prevent most damage to genes themselves, the rate of mutations increase as one gets older, because DNA damage forms a feedback loop.

Usually, oncogenes are dominant, as they contain gain of function mutations, while mutated tumor suppressors are recessive, as they contain loss of function mutations. Each cell has two copies of a same gene, one from each parent, and under most cases gain of function mutation in one copy of a particular proto-oncogene is enough to make that gene a true oncogene, while usually loss of function mutation need to happen in both copies of a tumor suppressor gene to render that gene completely non-functional. However, cases exist in which one loss of function copy of a tumor suppressor gene can render the other copy non-functional, and this is called dominant negative effect. This is observed in many p53 mutations.

Mutation of tumor suppressor genes that are passed on to the next generation of not merely cells, but their offspring can cause increased likelihoods for cancers to be inherited. Members within these families have increased incidence and decreased latency of multiple tumors. The mode of inheritance of mutant tumor suppressors is that affected member inherits a defective copy from one parent, and a normal copy from another. Because mutations in tumor suppressers act in a recessive manner (note, however, there are exceptions), the loss of the normal copy creates the cancer phenotype. For instance, individuals who are heterozygous for p53 mutations are often victims of Li-Fraumeni syndrome, and those who are heterozygous for Rb mutations develop retinoblastoma. Similarly, mutations in the adenomatous polyposis coli gene are linked to adenopolyposis colon cancer, with thousands of polyps in colon while young, while mutations in BRCA1 and BRCA2 lead to early onset of breast cancer.

Cancer is ultimately due to accumulation of genetic damage, which are fundamentally mutations in the DNA. Substances that cause these mutations are known as mutagens, and mutagens that cause cancers are known as carcinogens. Particular substances have been linked to specific types of cancer. Tobacco smoking is associated with lung cancer. Prolonged exposure to radiation, particularly ultraviolet radiation from the sun, leads to melanoma and other skin malignancies. Breathing asbestos fibers is associated with mesothelioma. In more general terms, chemicals called mutagens and free radicals are known to cause mutations. Other types of mutations can be caused by chronic inflammation, as neutrophil granulocytes secrete free radicals that damage DNA. Chromosomal translocations, such as the Philadelphia chromosome, are a special type of mutation that involve exchanges between different chromosomes.

Many mutagens are also carcinogens, but some carcinogens are not mutagens. Examples of carcinogens that are not mutagens include alcohol and estrogen. These are thought to promote cancers through their stimulating effect on the rate of cell mitosis. Faster rates of mitosis increasingly leave less oppurtunities for repair enzymes to repair damaged DNA during DNA replication, increasingly the likelihood of a genetic mistake. A mistake made during mitosis can lead to the daughter cells receiving the wrong number of chromosomes, which leads to aneuploidy and may lead to cancer.

Furthermore, many cancers originate from a viral infection; this is especially true in animals such as birds, but less so in humans, as viruses only responsible for 15% of human cancers. The mode of virally-induced tumors can be divided into two, acutely-transforming or slowly-transforming. In acutely transforming viruses, the viral particles carry a gene that encodes for a overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly-transforming viruses, the virus genome is inserted, especially as viral genome insertion is obligatory part of retroviruses, near a proto-oncogene in the host genome. The viral promoter or other transcription regulation elements in turn cause overexpression of that proto-oncogene, which in turn induces uncontrolled cellular proliferation. Because viral genome insertion is not specific to proto-oncogenes and the chance of insertion near that proto-oncogene is low, slowly-transforming viruses have very long tumor latency compared to acutely-transforming virus, which already carries the viral-oncogene.

It is impossible to tell the initial cause for any specific cancer. However, with the help of molecular biological techniques, it is possible to characterize the mutations or chromosomal aberrations within a tumor, and rapid progress is being made in the field of predicting prognosis based on the spectrum of mutations in some cases. For example, up to half of all tumors have a defective p53 gene. This mutation is associated with poor prognosis, since those tumor cells are less likely to go into apoptosis or programmed cell death when damaged by therapy. Telomerase mutations remove additional barriers, extending the number of times a cell can divide. Other mutations enable the tumor to grow new blood vessels to provide more nutrients, or to metastasize, spreading to other parts of the body.


Malignant tumors cells have distinct properties:

A cell that degenerates into a tumor cell does not usually acquire all these properties at once, but its descendant cells are selected to build them. This process is called clonal evolution. A first step in the development of a tumor cell is usually a small change in the DNA, often a point mutation, which leads to a genetic instability of the cell. The instability can increase to a point where the cell loses whole chromosomes, or has multiple copies of several. Also, the DNA methylation pattern of the cell changes, activating and deactivating genes without the usual regulation. Cells that divide at a high rate, such as epithelials, show a higher risk of becoming tumor cells than those which divide less, for example neurons.

Morphology

Tissue can be organized in a continuous spectrum from normal to cancer.
Enlarge
Tissue can be organized in a continuous spectrum from normal to cancer.

Cancer tissue has a distinctive appearance under the microscope. Among the distinguishing traits are a large number of dividing cells, variation in nuclear size and shape, variation in cell size and shape, loss of specialized cell features, loss of normal tissue organization, and a poorly defined tumor boundary. Immunohistochemistry and other molecular methods may characterise specific markers on tumor cells, which may aid in diagnosis and prognosis.

Biopsy and microscopical examination can also distinguish between malignancy and hyperplasia, which refers to tissue growth based on an excessive rate of cell division, leading to a larger than usual number of cells but with a normal orderly arrangement of cells within the tissue. This process is considered reversible. Hyperplasia can be a normal tissue response to an irritating stimulus, for example callus.

Dysplasia is an abnormal type of excessive cell proliferation characterized by loss of normal tissue arrangement and cell structure. Often such cells revert back to normal behavior, but occasionally, they gradually become malignant.

The most severe cases of dysplasia are referred to as "carcinoma in situ." In Latin, the term "in situ" means "in place", so carcinoma in situ refers to an uncontrolled growth of cells that remains in the original location and shows no propensity to invade other tissues. Nevertheless, carcinoma in situ may develop into an invasive malignancy and is usually removed surgically, if possible.

Heredity

Most forms of cancer are "sporadic", and have no basis in heredity. There are, however, a number of recognised syndromes of cancer with a hereditary component. Examples are:

Environment and diet

The incidence of lung cancer is highly correlated with smoking. Source:NIH.
Enlarge
The incidence of lung cancer is highly correlated with smoking. Source:NIH.

The most consistent finding, over decades of research, is the strong association between tobacco use and cancers of many sites. Hundreds of epidemiological studies have confirmed this association. Further support comes from the fact that lung cancer death rates in the United States have mirrored smoking patterns, with increases in smoking followed by dramatic increases in lung cancer death rates and, more recently, decreases in smoking followed by decreases in lung cancer death rates in men. Up to half of all cancer cases can be attributed to smoking, diet, and environmental pollution.

Epidemiology

In some Western countries, such as the USA[1] and the UK[2], cancer is overtaking cardiovascular disease as the leading cause of death. In many Third World countries cancer incidence (insofar as this can be measured) appears much lower, most likely because of the higher death rates due to infectious disease or injury. With the increased control over malaria and tuberculosis in some Third World countries, incidence of cancer is expected to rise; this is termed the iceberg phenomenon in epidemiological terminology.

Cancer epidemiology closely mirrors risk factor spread in various countries. Hepatocellular carcinoma (liver cancer) is rare in the West but is the main cancer in China and neighboring countries, most likely due to the endemic presence of hepatitis B and aflatoxin in that population. Similarly, with tobacco smoking becoming more common in various Third World countries, lung cancer incidence has increased in a parallel fashion.

Prevention

Cancer prevention is defined as active measures to decrease the incidence of cancer. This can be accomplished by avoiding carcinogens or altering their metabolism, pursuing a lifestyle or diet that modifies cancer-causing factors and/or medical intervention (chemoprevention, treatment of premalignant lesions).

Much of the promise for cancer prevention comes from observational epidemiologic studies that show associations between modifiable life style factors or environmental exposures and specific cancers. Evidence is now emerging from randomized controlled trials designed to test whether interventions suggested by the epidemiologic studies, as well as leads based on laboratory research, actually result in reduced cancer incidence and mortality.

Examples of modifiable cancer risk include alcohol consumption (associated with increased risk of oral, esophageal, breast, and other cancers), physical inactivity (associated with increased risk of colon, breast, and possibly other cancers), and being overweight (associated with colon, breast, endometrial, and possibly other cancers). Based on epidemiologic evidence, it is now thought that avoiding excessive alcohol consumption, being physically active, and maintaining recommended body weight may all contribute to reductions in risk of certain cancers; however, compared with tobacco exposure, the magnitude of effect is modest or small and the strength of evidence is often weaker. Other lifestyle and environmental factors known to affect cancer risk (either beneficially or detrimentally) include certain sexual and reproductive practices, the use of exogenous hormones, exposure to ionizing radiation and ultraviolet radiation, certain occupational and chemical exposures, and infectious agents.

Diet and cancer

The consensus on diet and cancer is that obesity increases the risk of developing cancer. Particular dietary practices often explain differences in cancer incidence in different countries (e.g. gastric cancer is more common in Japan, while colon cancer is more common in the United States). Studies have shown that immigrants develop the risk of their new country, suggesting a link between diet and cancer rather than a genetic basis.

Despite frequent reports of particular substances (including foods) having a beneficial or detrimental effect on cancer risk, few of these have an established link to cancer. These reports are often based on studies in cultured cell media or animals. Public health recommendations cannot be made on the basis of these studies until they have been validated in an observational (or occasionally a prospective interventional) trial in humans.

The case of beta-carotene provides an example of the necessity of randomized clinical trials. Epidemiologists studying both diet and serum levels observed that high levels of beta-carotene, a precursor to vitamin A, were associated with a protective effect, reducing the risk of cancer. This effect was particularly strong in lung cancer. This hypothesis led to a series of large randomized trials conducted in both Finland and the United States (CARET study) during the 1980s and 1990s. This study provided about 80,000 smokers or former smokers with daily supplements of beta-carotene or placebos. Contrary to expectation, these tests found no benefit of beta-carotene supplementation in reducing lung cancer incidence and mortality. In fact, the risk of lung cancer was slightly, but significantly, increased in smokers, leading to an early termination of the study[3].

Other chemoprevention agents

Daily use of tamoxifen, a selective estrogen receptor modulator, for up to 5 years, has been demonstrated to reduce the risk of developing breast cancer in high-risk women by about 50%. Cis-retinoic acid also has been shown to reduce risk of second primary tumors among patients with primary head and neck cancer. Finasteride, a 5-alpha reductase inhibitor, has been shown to lower the risk of prostate cancer. Other examples of drugs that show promise for chemoprevention include COX-2 inhibitors (which inhibit a cyclooxygenase enzyme involved in the synthesis of proinflammatory prostaglandins).

Genetic testing

Genetic testing for high-risk individuals, with enhanced surveillance, chemoprevention, or risk-reducing surgery for those who test positive, is already available for certain cancer-related genetic mutations.

Diagnosing cancer

Most cancers are initially recognized either because signs or symptoms appear or through screening. Neither of these lead to a definitive diagnosis, which usually requires the opinion of a pathologist.

Signs and symptoms

Roughly, cancer symptoms can be divided into three groups:

Every single item in the above list can be caused by a variety of conditions (a list of which is referred to as the differential diagnosis). Cancer may be a common or uncommon cause of each item.

Biopsy

A cancer may be suspected for a variety of reasons, but the definitive diagnosis of most malignancies must be confirmed by histological examination of the cancerous cells by a pathologist. Tissue can be obtained from a biopsy or surgery. Many biopsies (such as those of the skin, breast or liver) can be done in a doctor's office. Biopsies of other organs are performed under anesthesia and require surgery in an operating room.

The tissue diagnosis indicates the type of cell that is proliferating, its histological grade and other features of the tumor. Together, this information is useful to evaluate the prognosis of this patient and choose the best treatment. Cytogenetics and immunohistochemistry may provide information about future behavior of the cancer (prognosis) and best treatment.

Screening

Cancer screening is an attempt to detect unsuspected cancers in the population. Screening tests suitable for large numbers of healthy people must be relatively affordable, safe, noninvasive procedures with acceptably low rates of false positive results. If signs of cancer are detected, more definitive and invasive followup tests are performed to confirm the diagnosis.

Screening for cancer can lead to earlier diagnosis. Early diagnosis may lead to extended life. A number of different screening tests have been developed. Breast cancer screening can be done by breast self-examination. Screening by regular mammograms detects tumors even earlier than self-examination, and many countries use it to systematically screen all middle-aged women. Colorectal cancer can be detected through fecal occult blood testing and colonoscopy, which reduces both colon cancer incidence and mortality, presumably through the detection and removal of premalignant polyps. Similarly, cervical cytology testing (using the Pap smear) leads to the identification and excision of precancerous lesions. Over time, such testing has been followed by a dramatic reduction of cervical cancer incidence and mortality. Testicular self-examination is recommended for men beginning at the age of 15 years to detect testicular cancer. Prostate cancer can be screened for by a digital rectal exam along with prostate specific antigen (PSA) blood testing.

Screening for cancer is controversial in cases when it is not yet known if the test actually saves lives. The controversy arises when it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments. For example: when screening for prostate cancer, the PSA test may detect small cancers that would never become life threatening, but once detected will lead to treatment. This situation, called overdiagnosis, puts men at risk for complications from unnecessary treatment such as surgery or radiation. Followup procedures used to diagnose prostate cancer (prostate biopsy) may cause side effects, including bleeding and infection. Prostate cancer treatment may cause incontinence (inability to control urine flow) and erectile dysfunction (erections inadequate for intercourse). Similarly, for breast cancer, there have recently been criticisms that breast screening programs in some countries cause more problems than they solve. This is because screening of women in the general population will result in a large number of women with false positive results which require extensive follow-up investigations to exclude cancer, leading to having a high number-to-treat (or number-to-screen) to prevent or catch a single case of breast cancer early.

Cervical cancer screening via the Pap smear has the best cost-benefit profile of all the forms of cancer screening from a public health perspective as, being a cancer, it has clear risk factors (sexual contact), and the natural progression of cervical cancer is that it normally spreads slowly over a number of years therefore giving more time for the screening program to catch it early. Moreover, the test itself is easy to perform and relatively cheap.

For these reasons, it is important that the benefits and risks of diagnostic procedures and treatment be taken into account when considering whether to undertake cancer screening.

Use of medical imaging to search for cancer in people without clear symptoms is similarly marred with problems. There is a significant risk of detection of what has been recently called an incidentaloma - a benign lesion that may be interpreted as a malignancy and be subjected to potentially dangerous investigations.

Treatment of cancer

Cancer can be treated by surgery, chemotherapy, radiation therapy, immunotherapy or other methods. The choice of therapy depends upon the location and grade of the tumor and the stage of the disease, as well as the general state of the patient (performance status). A number of experimental cancer treatments are also under development.

Complete removal of the cancer without damage to the rest of the body is the goal of treatment. Sometimes this can be accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness. The effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. Radiation can also cause damage to normal tissue.

Because "cancer" refers to a class of diseases, it is unlikely that there will ever be a single "cure for cancer" any more than there will be a single treatment for all